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Introduction: We developed an innovative approach for malig-
nant pleural mesothelioma (MPM) with a short accelerated course 
of high-dose hemithoracic intensity-modulated radiation therapy 
(IMRT) followed by extrapleural pneumonectomy (EPP). This phase 
I/II study assessed the feasibility of Surgery for Mesothelioma After 
Radiation Therapy (SMART).
Methods: All resectable clinical T1-3N0M0 histologically proven, 
previously untreated MPMs were eligible. Patients received 25 Gy in 
five daily fractions during 1 week to the entire ipsilateral hemithorax 
with concomitant 5 Gy boost to areas at risk followed by EPP within 
1 week of completing neoadjuvant IMRT. Adjuvant chemotherapy 
was offered to ypN2 patients on final pathologic findings. The pri-
mary end point was treatment-related mortality and secondary end 
points were overall survival, disease-free survival, treatment-related 
morbidity, and patterns of failure.
Results: Targeted accrual of 25 patients was completed between 
November 2008 and October 2012. All patients completed SMART. 
IMRT was well tolerated with no grade 3+ toxicities. EPP was per-
formed 6 ± 2 days after completing IMRT without any perioperative 
mortality. Thirteen patients developed grade 3+ surgical complica-
tions. One patient (4%) died from treatment-related toxicity (empy-
ema) during follow-up. All but one patient had stage III or IV disease 
on final pathologic findings. Five of 13 ypN2 patients received adju-
vant chemotherapy. After a median follow-up of 23 months (range, 
6–51), the cumulative 3-year survival reached 84% in epithelial sub-
types compared with 13% in biphasic subtypes (p = 0.0002).
Conclusions: SMART is feasible in resectable MPM patients. 
This innovative protocol presents encouraging results and supports 
future studies looking at long-term outcome in patients with epi-
thelial subtypes.
Key Words: Mesothelioma, Neoadjuvant therapy, Hemithoracic 
radiotherapy, High-dose radiation, Accelerated radiation, Extrapleural 
pneumonectomy, Multimodality therapy.
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Industrialized countries are currently at the peak of an epi-demic of malignant pleural mesothelioma (MPM).1 The inci-
dence is expected to plateau by 2020 because asbestos has been 
banned for more than 30 years in most of these countries.2–4 
However, the consumption of asbestos continues to increase in 
many areas of the world where its usage has not been regulated 
and could lead to a new surge of MPM in the near future.1
The overall prognosis of MPM is grim and treatment 
outcomes are disappointing. The median survival is 4 to 12 
months without treatment and the 2-year overall survival is 
0% to 12%.5–7 Various therapeutic approaches, from best sup-
portive care to multimodal therapy, have been studied. The 
most aggressive therapy includes an extrapleural pneumo-
nectomy (EPP) where the affected lung, pleural lining, dia-
phragm, pericardium, and areas of suspected involvement 
such as chest wall and lymph nodes are resected en bloc. The 
optimal treatment options for patients with resectable MPM 
remain controversial, but investigators at the most recent 
meeting from the International Mesothelioma Interest Group 
agreed that complete macroscopic surgical resection plays a 
vital role in the multimodality therapy of MPM, as is the case 
for other solid malignancies.8–10
In our experience, neoadjuvant chemotherapy followed 
by EPP and adjuvant hemithoracic intensity-modulated radia-
tion therapy (IMRT) achieved a cumulative 3-year survival of 
53% with a median survival of 59 months in patients with ypN0 
disease who completed all three modalities.11 We and others 
observed that hemithoracic radiation was particularly success-
ful to achieve local control after EPP.12–14 Unfortunately, the 
success of hemithoracic radiation is limited by distant fail-
ures, the most common sites being the abdominal peritoneal 
cavity and contralateral lung.11,13
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A possible mechanism for this pattern of distant fail-
ure is inadvertent tumor spillage at time of EPP. If true, this 
suggests a possible theoretical advantage with neoadjuvant 
treatment designed to control the proliferative ability of clo-
nogens spilt intraoperatively by means of tumoricidal and/or 
tumorostatic effects to prevent distant seeding. We, therefore, 
developed a new protocol with a short accelerated course of 
high-dose hypofractionated hemithoracic radiation followed 
by EPP in the hopes to improve radiation delivery and sur-
vival. We report the results of a seamless phase I/II study test-
ing the safety and feasibility of Surgery for Mesothelioma 
After Radiation Therapy (SMART).
METHODS
We conducted a two-step combined phase I/II pro-
spective single cohort clinical feasibility study on surgically 
resectable MPM (Fig. 1). Eligible patients were at least 18 
years of age, Eastern Cooperative Oncology Group perfor-
mance status of 0 to 2, with good pulmonary function tests 
(defined as forced expiratory volume in 1 second >40% pre-
dicted or diffusing capacity of the lungs for carbon monoxide 
>45% predicted), a new histological diagnosis of MPM previ-
ously untreated, clinical stage T1-3N0M0, suitable for com-
bined modality therapy, and able to give informed consent. 
Clinical stage was determined by computed tomography (CT) 
scan of the chest and abdomen, positron emission tomography 
(PET)-CT scan, and brain magnetic resonance imaging or CT. 
Preoperative nodal sampling with endobronchial ultrasound 
(EBUS) or mediastinoscopy was not routinely performed. 
The protocol was approved by our institutional review board. 
Written informed consent was obtained from each patient.
The clinical target volume is defined as the ipsilateral 
hemithorax, from the thoracic inlet down to the diaphragmatic 
insertion, including biopsy and drainage tract sites. The gross 
tumor volume is defined as any tumor seen on imaging (such as 
CT and PET). The dose prescription to the clinical target volume 
is 25 Gy in five daily fractions during approximately 1 week 
with a concomitant boost of 5 Gy to the gross tumor volume 
and tract sites. Typically, a multibeam IMRT technique is used. 
The complete details of IMRT will be published separately.
All patients underwent EPP within 1 week of complet-
ing the neoadjuvant IMRT. Surgery was completed accord-
ing to a standard technique as previously described.11,15 EPP 
specimens were reviewed and reported by at least one sub-
specialty thoracic pathologist (M-ST or DMH). Histological 
diagnosis and staging were on the basis of the World Health 
Organization classification system and tumor, node, metas-
tasis (TNM) staging system.16,17 Cases demonstrating medi-
astinal lymph node involvement (i.e., ypN2) were offered 
adjuvant chemotherapy, usually cisplatin and an antifolate, 
either raltitrexed or pemetrexed (as per the discretion of the 
medical oncologists), within 24 weeks after EPP.
After completing therapy, patients were followed every 
4 weeks until 3 months; every 6 weeks until 6 months; every 
2 months until 12 months; every 3 months until 2 years; and 
then every 6 months for 5 years. At each follow-up, a com-
plete history, physical examination, and Eastern Cooperative 
Oncology Group performance status were recorded in addi-
tion to morbidity and mortality status. Routine tests included 
complete blood count, liver profile, creatinine, and chest 
radiograph. CT scan of the thorax and abdomen were done 
at 3, 6, 12, 18, and 24 months and then yearly afterward. 
Additional tests were done at the discretion of the oncologist. 
Recurrences were diagnosed clinically, usually by serial imag-
ing and proven pathologically when feasible.
The study aim is to evaluate the feasibility of SMART. 
The primary end point is that the proportion of patients 
treated with grade 5 (G5) treatment–related mortality should 
not exceed 8%. The secondary aims are (1) to evaluate acute 
and late morbidity related to treatment; (2) to evaluate local 
recurrence, distant recurrence, disease-free survival, and 
overall survival rates; and (3) to identify factors and param-
eters associated with increased risk of treatment morbidity. 
 Treatment-related toxicity was defined by the CTCAE v3.18
Statistics
The initial pilot phase I study had a planned accrual of 
12 patients. The risk of perioperative surgical mortality and 
morbidity (defined by 30-day or in-hospital grade 3–5 com-
plications according to CTCAE v3) associated with EPP was 
anticipated to be 8% and 35%, respectively, on the basis of 
our previous experience.19 We assumed Bayesian posterior 
Study Schema
Observation
ypN0-1
Adjuvant
Chemotherapy
ypN2
<26 weeks post-op
Extrapleural Pneumonectomy
1 week post-RT
Neoadjuvant Hemithoracic
Intensity Modulated Radiotherapy
(25 Gy/5 fx +/- concomitant
5 Gy boost over 1 week)
Histologically Proven, Previously Untreated
 Malignant Pleural Mesothelioma (cT1-3 N0 M0)
Baseline Investigations, Informed Consent
FIGURE 1.  Study schema. RT, radiotherapy.
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probability stopping rules with a sample size of 12, a priori 
probability of 0.08 for mortality (G5), and 0.35 for seri-
ous morbidity (G3+) with a confidence level of 0.95 that 
the (study) posterior probability was worse than the a priori 
probability.
On-going marginal posterior probability analysis with 
these assumptions gave the following stopping boundaries: if 
there were ≤1 treatment-related deaths (or ≤3 serious morbid-
ity) in the first quartet of patients, then accrue second quartet; 
if there were ≤2 treatment-related deaths (or ≤5 serious mor-
bidity) in total after the second quartet, then accrue third quar-
tet (total of 12 patients). If there were ≤3 treatment-related 
deaths (or ≤7 serious morbidity) in the first 12 patients, we 
expanded to a phase 2 study and accrued an additional 13 
patients (total of 25 patients) using the same protocol.
The analysis of the feasibility study was primarily 
descriptive. The proportion of patients treated without a major 
protocol violation as well as acute and long-term morbidity 
and mortality was collected. The cumulative rate of local and 
distant tumor recurrence was determined using the Kaplan–
Meier method. The identification of factors associated with 
increased risk of treatment morbidity was determined by 
using the Student’s t test for continuous variables and either 
χ2 test or Fisher’s exact test for categorical variables. Variables 
tested were age, sex, side of tumor, histology, and stage of dis-
ease. Survival curves were compared using the log-rank test. 
Threshold for statistical significance was 0.05.
RESULTS
The accrual goal of 25 patients was completed 
between November 2008 and October 2012. Patient infor-
mation is presented in Table 1. A total of 138 patients were 
seen during the same time frame and 82% were not eligible 
for the study because of advanced disease (n = 70), presence 
of comorbidities (n = 28), or patients’ refusal (n = 15). All 
25 patients completed their intended IMRT and EPP. IMRT 
was well tolerated with no grade 3 to 5 toxicities (G3+). The 
most common grade 1 and 2 symptoms related to the IMRT 
were fatigue, nausea, and esophagitis. EPP was performed 
6 ± 2 days after completion of IMRT. All but one patient had 
resection of the diaphragm and pericardium along with the 
parietal pleura and lung. In two patients, a chest wall resec-
tion of three ribs was required to achieve complete macro-
scopic resection.
Thirteen patients (52%) developed G3+ surgical com-
plications (Table 2). The main G3+ complication was atrial 
fibrillation, occurring in five patients. No patients died within 
30 days of surgery or during the postoperative hospital stay. 
One patient (4%) died from treatment-related complication 
(empyema) during follow-up at 88 days. Despite the preop-
erative radiation, no patient developed bronchopleural fistula 
immediately after surgery or during follow-up. The median 
length of stay after EPP was 12 days (range, 5–51 days). Age 
was the only factor potentially associated with increased risk 
of G3+ complications (66 ± 7 versus 60 ± 8 years in patients 
without G3+ complications; p = 0.06).
All but one patient were stage III (n = 11) or IV (n = 13) on 
final pathologic findings. One patient with biphasic histologic 
subtype had stage IB disease. Five of 13 patients (38%) with 
ypN2 disease underwent three to six cycles (median, 4 cycles) 
of adjuvant chemotherapy.
After a median follow-up of 23 months (range, 6–51 
months), the cumulative overall survival reached 58% at 
3 years (Fig. 2) The 3-year survival was significantly better 
for epithelial compared with biphasic histologic subtypes 
(Fig. 3). At 3 years, the cumulative survival reached 84% and 
disease-free survival 65% in patients with epithelial histologic 
subtype (Fig. 4). All patients with epithelial, ypT3 or ypT4, 
N2-negative disease were alive at last follow-up and only one 
(ypT4N0) developed recurrence.
TABLE 1.  Patient and Tumor Demographics
Age (yr) 64 ± 8
Sex
  Male 19
  Female 6
Laterality
  Right 21
  Left 4
Clinical T stage
  T1 4
  T2 15
  T3 6
Final histology
  Epithelial 16
  Biphasic 9
Pathological stage
  IB 1
  III 11
  IV 13
ypTNM
  T1bN0M0 1
  T3N0M0 7
  T3N2M0 4
  T4N0M0 3
  T4N1M0 1
  T4N2M0 8
  T4N3M0 1
TABLE 2.  Complications after SMART
Grade 0 1 2 3 4 5
Thromboembolic event 22 0 1 1 1 0
Atrial fibrillation 15 0 5 5 0 0
Wound infection 22 0 2 1 0 0
Chylothorax 23 0 0 2 0 0
Hemothorax 24 0 0 0 1 0
Wound dehiscence 21 1 2 1 0 0
Renal dysfunction 24 0 0 1 0 0
Pneumonia 24 0 0 0 1 0
Empyema 23 0 0 1 0 1
Some patients can present more than one complication.
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Overall, 11 patients developed recurrence (7 biphasic 
and 4 epithelial subtypes). Recurrences were in the ipsilat-
eral chest only (n = 2, 18%), ipsilateral chest and distant sites 
(n = 3, 27%), and distant sites only (n = 6, 55%). Distant sites 
of recurrences were located in the retro-peritoneal lymph 
nodes (n = 3), peritoneal cavity (n = 3), liver (n = 1), contralat-
eral lung parenchyma (n = 4), and contralateral pleura (n = 1).
DISCUSSION
This study demonstrates for the first time that EPP after 
a short accelerated course of high-dose hemithoracic radia-
tion is feasible. The radiation was extremely well tolerated 
with no grade 3+ toxicity and all patients proceeded to EPP 
within the predefined time frame with no perioperative mor-
tality. Grade 3+ toxicity developed in 13 patients (52%) after 
surgery and included predominantly atrial fibrillation. We 
observed remarkably good outcomes in patients with epithe-
lial histologic subtypes with a 3-year survival of 84% after a 
median follow-up of 23 months. At the last follow-up, only 
one of nine patients with epithelial N2-negative disease had 
developed recurrence despite the fact that all tumors were 
pathologic staged ypT3 and ypT4. Although longer follow-up 
and larger number of patients are required to make definitive 
conclusions on the long-term impact of this treatment proto-
col, these initial results are extremely encouraging for patients 
with epithelial MPM.
Nonepithelial histology was the most significant nega-
tive prognostic factors, confirming the findings of others.20,21 
In this trial, most patients with biphasic tumor recurred within 
18 months, suggesting that nonepithelial histology are likely 
not as radio-sensitive as epithelial subtypes to high-dose hypo-
fractionated radiation. Hence, patients with biphasic disease 
should potentially be treated with a different approach than 
accelerated high-dose hemithoracic radiation and EPP.
Although the presence and the number and distribution 
of nodes are important predictors for survival, we elected not 
to perform systematic mediastinoscopy and/or EBUS in this 
initial phase I/II study.22 Mediastinoscopy and EBUS have a 
poor negative predictive value to rule out N2 disease and we 
thus decided not to exclude patients with potentially low-bulk 
N2 disease from this protocol as long as the CT and PET scan 
were negative for N2 disease.12,23 Furthermore, the impact of 
neoadjuvant IMRT on low-burden N2 disease was unknown 
and important to assess.
Despite the large number of right-sided EPP, which 
has been reported to be a risk factor for perioperative mor-
tality,19,24 we observed only one treatment-related death after 
discharge from hospital in a patient with biphasic left-sided 
disease in this series of patients. Overall, our morbidity rate 
was similar to other surgical series with a 52% rate of grade 3 
or 4 complications.24–26 Noteworthy, three patients developed 
venous thromboembolic event after discharged from hospi-
tal, and our protocol was therefore modified during the study 
to maintain patients on venous thromboembolic prophylaxis 
after discharged from hospital for at least a month.
The SMART protocol has several advantages 
related to the accelerated course of treatment. However, all 
patients must proceed to EPP after IMRT to avoid potential 
 radiation-induced pulmonary toxicity. The protocol there-
fore requires a high degree of coordination and cooperation 
between radiation oncology and thoracic surgery. This may 
hamper its implementation in centers where multidisciplinary 
interest is lacking.
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FIGURE 2.  Overall survival as an intention-to-treat analysis 
of all patients undergoing Surgery for Mesothelioma After 
Radiation Therapy.
Survival by histology
0 12 24 36
0
10
20
30
40
50
60
70
80
90
100
Epithelial
Biphasic
p=0.0002
Patients at risk
Epithelial 16     12    5 3
Biphasic   9  3    1      1
Months after radiation
Su
rv
iv
al
 (%
)
FIGURE 3.  Overall survival for patients with epithelial and 
biphasic subtypes.
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FIGURE 4.  Disease-free survival for patients with epithelial 
and biphasic subtypes.
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The therapeutic indication for SMART differs from 
standard induction protocols of radiation and chemoradia-
tion because the short time course of radiation does not allow 
meaningful cytoreductive down staging. SMART aims to 
induce a tumorostatic and tumoricidal effect to prevent or 
delay the successful implantation of clonogens to distant sites 
at time of EPP and thereafter. In addition, increasing evidence 
suggest that the mechanisms of action of high-dose hypo-
fractionated radiation differ from standard radiation in that 
the response is partly because of a specific activation of the 
immune system against the tumor rather than only a direct 
cytotoxic effect from the ionizing radiation.27,28 Hence, our 
protocol of high-dose radiation and surgery could provide a 
net benefit on the immune system by activating the immune 
system against the tumor and then removing the immunosup-
pressive environment generated by the tumor. The impact on 
the immune system of high-dose hypofractionated radiation 
therapy will potentially open the door for new combination 
therapies in the near future between immunotherapy and radi-
ation to optimize their synergism on the immune system.28,29 
This combined strategy will potentially be particularly valu-
able for patients with MPM.
Our study has several limitations related to the fact 
that this is a nonrandomized, single cohort phase I/II study. 
Hence, patient selection is a potential confounding factor. We 
note, however, that 18% of our patients were included into 
this trial during the 4-year period, which is similar to previ-
ously reported surgical series where typically 17% to 19% of 
patients screened in clinic are eligible for EPP.8,20 In addition, 
only one of 25 patients was found to have stage IB on final 
pathologic findings, suggesting that our population of patients 
had relatively advanced disease.
Normally, we would proceed to a phase 3 randomized trial 
but, as the Mesothelioma and Radical Surgery (MARS) trial 
showed, mounting such a study will likely be challenging and 
perhaps impossible.8 Most patients are reluctant to be random-
ized in a study with widely disparate treatment options. Although 
equipoise among the clinicians exist, patients often have strong 
treatment biases and may refuse randomization out right. MPM 
are rare tumors and these cases are technically challenging with 
a steep learning curve. Such cases are usually best handled by a 
dedicated radiation oncologist and thoracic surgeon to maintain 
volume of practice and retain technical expertise.
In conclusion, for the first time we have demonstrated 
that SMART is feasible in resectable MPM patients. Although 
larger number of patients and longer follow-up are required, 
this innovative protocol may potentially improve survival in 
selected epithelial MPM patients.
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